Legal & General Group Portfolio holdings
Legal & General Group Plc, founded in 1836 by six lawyers in London, is a British multinational financial services company headquartered in London, renowned for its leadership in insurance, pensions, and investment management. Managing trillions in assets, the firm operates through key divisions like Legal & General Investment Management (LGIM), one of the UK’s largest asset managers, focusing on index funds, active strategies, and sustainable investing for institutional clients like pension funds. It also provides life insurance, retirement products, and general insurance, serving millions of customers with a strong emphasis on long-term financial security and infrastructure investment, such as affordable housing. With a heritage of stability and a modern push toward ESG (environmental, social, governance) principles, Legal & General remains a cornerstone of the UK financial landscape with a growing global presence.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$657M |
| 2 |
Apple
AAPL
|
+$610M |
| 3 |
Amazon
AMZN
|
+$587M |
| 4 |
AstraZeneca
AZN
|
+$319M |
| 5 |
Snowflake
SNOW
|
+$272M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$323M |
| 2 |
MXIM
Maxim Integrated Products
MXIM
|
+$273M |
| 3 |
WORK
Slack Technologies, Inc.
WORK
|
+$121M |
| 4 |
PFPT
Proofpoint, Inc.
PFPT
|
+$98.6M |
| 5 |
JD.com
JD
|
+$89.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.03% |
| 2 | Financials | 13.72% |
| 3 | Healthcare | 12.6% |
| 4 | Consumer Discretionary | 10.97% |
| 5 | Communication Services | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2251
ADT
ADT
$5.58B
| $998K | ﹤0.01% |
123,355
+31,079
| +34% | +$286K |
|
|
BRFS
2252
DELISTED
BRF SA
BRFS
| $985K | ﹤0.01% |
196,021
| – | – |
|
2253
iShares MSCI Emerging Markets ETF
EEM
$29.5B
| $980K | ﹤0.01% |
19,459
-49,241
| -72% | -$2.56M |
|
|
BRSP
2254
BrightSpire Capital
BRSP
$648M
| $976K | ﹤0.01% |
103,937
+43,896
| +73% | +$424K |
|
2255
American Vanguard Corp
AVD
$68.9M
| $967K | ﹤0.01% |
64,228
+4,575
| +8% | +$72.3K |
|
2256
Rayonier Advanced Materials
RYAM
$610M
| $965K | ﹤0.01% |
128,721
+591
| +0.5% | +$4.07K |
|
|
DM
2257
DELISTED
Desktop Metal, Inc.
DM
| $960K | ﹤0.01% |
13,398
+10,931
| +443% | +$949K |
|
2258
National Presto Industries
NPK
$989M
| $956K | ﹤0.01% |
11,644
+418
| +4% | +$37.5K |
|
|
HAYN
2259
DELISTED
Haynes International, Inc.
HAYN
| $956K | ﹤0.01% |
25,660
| – | – |
|
2260
Revolve Group
RVLV
$1.73B
| $951K | ﹤0.01% |
15,397
+9,788
| +175% | +$637K |
|
|
LOGC
2261
DELISTED
ContextLogic
LOGC
| $949K | ﹤0.01% |
+5,796
| New | +$1.44M |
|
2262
Petco
WOOF
$794M
| $948K | ﹤0.01% |
44,927
+10,700
| +31% | +$226K |
|
2263
Celestica
CLS
$36.5B
| $947K | ﹤0.01% |
106,640
-49,125
| -32% | -$421K |
|
2264
Immunocore
IMCR
$1.73B
| $933K | ﹤0.01% |
25,277
+6,186
| +32% | +$209K |
|
2265
Workhorse Group
WKHS
$36.3M
| $917K | ﹤0.01% |
40
+14
| +54% | +$424K |
|
2266
Celldex Therapeutics
CLDX
$3.28B
| $906K | ﹤0.01% |
16,770
+10,667
| +175% | +$501K |
|
2267
Huron Consulting
HURN
$2.42B
| $903K | ﹤0.01% |
17,357
+4,500
| +35% | +$219K |
|
2268
Kearny Financial
KRNY
$599M
| $899K | ﹤0.01% |
72,357
+14,977
| +26% | +$185K |
|
|
RVNC
2269
DELISTED
Revance Therapeutics, Inc.
RVNC
| $896K | ﹤0.01% |
32,175
+13,296
| +70% | +$379K |
|
|
PVG
2270
DELISTED
PRETIUM RESOURCES INC.
PVG
| $890K | ﹤0.01% |
92,017
+9,134
| +11% | +$87.2K |
|
2271
Hudbay
HBM
$12.3B
| $888K | ﹤0.01% |
142,457
-105,693
| -43% | -$669K |
|
2272
Rocket Pharmaceuticals
RCKT
$394M
| $887K | ﹤0.01% |
29,681
+7,566
| +34% | +$275K |
|
|
CONN
2273
DELISTED
Conn's Inc.
CONN
| $886K | ﹤0.01% |
38,848
-347
| -0.9% | -$8.24K |
|
2274
OR Royalties Inc
OR
$6.2B
| $876K | ﹤0.01% |
77,979
-15,594
| -17% | -$195K |
|
|
CTEV
2275
Claritev Corp
CTEV
$556M
| $874K | ﹤0.01% |
3,878
+2,781
| +254% | +$752K |
|
Similar funds
Legal & General Group's Q3 2021 Portfolio in Review
As of Q3 2021, Legal & General Group held 3,551 positions worth $308B, up 2.9% from $299B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Legal & General Group deployed $10.7B of net new capital in Q3 2021, opening 77 new positions and adding to 2,293 existing holdings. Its largest new stake was AstraZeneca: 2,738,007 shares worth $329M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was JD.com, an estimated $89.3M trimmed.
- Legal & General Group's largest Q3 2021 buy was AstraZeneca: 2,738,007 shares worth $329M.
- Legal & General Group added most to Microsoft in Q3 2021, an estimated $657M increase.
- Legal & General Group's biggest Q3 2021 reduction was JD.com, cutting an estimated $89.3M.
- Legal & General Group fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $323M.
- Legal & General Group's ten largest holdings make up 22% of its $308B portfolio in Q3 2021.
- Legal & General Group opened 77 new positions and closed 55 in Q3 2021.
- Legal & General Group's portfolio value rose 2.9% quarter-over-quarter to $308B.
Based on Legal & General Group's 13F filing for Q3 2021, filed 15 Nov 2021.